On September 1, 2026, WIRED published Kate Knibbs's investigation into what it calls the perimenopause industrial complex — a long-form account of how telehealth startups, MAHA-aligned political operatives and mainstream medical experts converged to make hormone therapy a mass-market consumer category, and of the clinicians now warning that the pendulum has swung too far. It is the most complete map yet of a market that has reshaped women's sexual and midlife health in under a year.

Why It Matters

For the sexual wellness industry this is the single most consequential adjacent market of the past year, and it cuts both ways. Low libido, vaginal dryness and painful sex are core perimenopause symptoms and core sexual wellness categories, and the FDA's label change plus the telehealth boom have done more to normalize clinical conversation about midlife sexual function than a decade of destigmatization marketing. Brands from Reckitt (which just put Durex and K-Y through GenM menopause certification) to Daré Bioscience (advancing a compounded 503B hormone ring for 2027) are positioning into the same demand curve. The risk is that the category is being built on a business model — cash-pay, compounded, subscription, minimal oversight, unbounded symptom list — that has a well-documented failure mode. If the correction comes as an FTC action on claims, a compounding-pharmacy enforcement wave, or a high-profile safety story, the spillover will hit sexual wellness brands that hitched their menopause positioning to the same wagon. Watch three things: whether the rewritten FDA labels land on schedule and how narrowly they are drawn; whether commercial payers follow Midi into reimbursement or leave the category cash-pay; and whether the Menopause Society moves from Faubion's on-the-record misgivings to formal guidance that constrains the marketing.

The demand data is the headline. Per an analysis SimilarWeb conducted for WIRED, four leading perimenopause startups — Midi, Winona, Alloy and Evernow — saw a 490% increase in web traffic between 2023 and 2026, which SimilarWeb characterized as an "organic demand surge." The trigger was regulatory: on November 10, 2025 the FDA announced it would remove the "black box" warnings that had sat on estrogen-containing hormone therapy products since the fallout from the 2002 Women's Health Initiative, with labels to be rewritten with age-specific guidance favoring initiation within 10 years of menopause onset. Harvard Health noted at the time that the changes were expected within roughly six months. HHS Secretary Robert F. Kennedy Jr. announced the move as "challenging outdated thinking."

The revolving-door detail is the one worth flagging for anyone modeling regulatory risk in this category. Speaking at the same press conference was Alicia Jackson, director of ARPA-H — the HHS advanced research agency — who had joined the administration less than a month earlier from her prior role as founder of the perimenopause telehealth company Evernow. Jackson told WIRED that "the earlier that you start hormone therapy, the greater the benefit," and criticized what she characterized as the medical establishment's "weird paternalism" in prescribing birth control readily while resisting hormone therapy.

The commercial mechanics are familiar to anyone who watched compounded GLP-1s: telehealth normalization plus consumer comfort with compounded formulations plus "turnkey" white-label services that WIRED reports can stand up a new virtual hormone clinic within days. More than 43 million US women are aged 35 to 54. Midi — the category's first unicorn, and one of the few players accepting commercial insurance — competes against out-of-pocket subscriptions running up to $200 a month, with larger telehealth firms including Hers now entering. Amy Schumer, a Midi investor, appears in advertising reciting a symptom list; the company's public position is that menopause has more than 100 possible symptoms, a roster that WIRED notes includes body odor, sensitive teeth, dry skin and asthma. Winona sells an estrogen-containing skincare product it markets for wrinkles.

That symptom inflation is where the clinical establishment pushes back — and notably, the pushback comes from inside the church. Stephanie Faubion, director of the Mayo Clinic's Center for Women's Health and medical director of the Menopause Society, told WIRED the hype machine "has gotten completely out of hand" in promoting hormone therapy for longevity or generalized fatigue, adding: "We are running into a danger zone attributing all these symptoms to perimenopause." Yale gynecologist Mary Jane Minkin, an outspoken advocate for patient awareness of treatment options, was more equivocal but landed in a similar place on causation: "Attributing everything in the world to perimenopause is tricky." There is no lab test that establishes perimenopause — unpredictable hormone variation is its defining feature — so the diagnosis rests on patient self-report, which is precisely what makes the addressable market so elastic.

Sources

Update — 2026-09-03

Initial entry — story first created.